New England Journal of Medicine MAY 21, 2009

Early versus Delayed Invasive Intervention in Acute Coronary Syndromes

Shamir R. Mehta, Christopher B. Granger, William E. Boden, Philippe Gabriel Steg, et al. for the TIMACS Investigators

Bottom Line

The TIMACS trial demonstrated that an early invasive strategy did not significantly reduce the risk of death, myocardial infarction, or stroke at 6 months compared to a delayed invasive strategy in patients with non-ST-elevation acute coronary syndromes (NSTE-ACS), although it provided a benefit in patients at high risk.

Key Findings

1. The primary composite outcome of death, new myocardial infarction, or stroke at 6 months occurred in 9.6% of patients in the early invasive group and 11.3% in the delayed group (HR 0.85, 95% CI 0.68–1.06, p = 0.15).

2. In a prespecified subgroup analysis of patients at high risk (GRACE score >140), early invasive strategy significantly reduced the risk of the primary composite outcome (13.9% vs. 21.0%, HR 0.65, 95% CI 0.48–0.89, p = 0.006).

3. The secondary outcome of death, myocardial infarction, or refractory ischemia was significantly lower in the early invasive group (9.5% vs. 12.9%, HR 0.72, 95% CI 0.58–0.89, p = 0.003), largely driven by a reduction in refractory ischemia.

4. Major bleeding rates during the index hospitalization were not significantly different between the early (3.1%) and delayed (3.5%) groups (p = 0.55).

Study Design

Design

RCT

Open-Label

Sample

3,031

Patients

Duration

6 mo

Median

Setting

Multicenter, international

Population Patients with unstable angina or NSTEMI with high-risk features (age >60, ischemic ECG changes, or elevated cardiac biomarkers)

Intervention Routine early invasive strategy with coronary angiography performed within 24 hours of randomization

Comparator Delayed invasive strategy with coronary angiography performed at least 36 hours after randomization

Outcome Composite of death, new myocardial infarction, or stroke at 6 months

Study Limitations

• A relatively high cross-over rate occurred, with 20.5% of patients in the delayed arm receiving earlier-than-scheduled interventions, which likely diluted the treatment effect in an intention-to-treat analysis.

• The study was powered based on an expected larger benefit, potentially rendering it underpowered to detect smaller but clinically relevant differences in the overall population.

• The trial definition of 'early' (within 24 hours) and 'delayed' (after 36 hours) may not capture potential benefits or harms of 'very early' intervention (e.g., <2–6 hours).

Clinical Significance

For the majority of patients with NSTE-ACS, a delayed invasive strategy is an acceptable and safe alternative to urgent intervention. However, in patients identified as being at high risk for clinical events (e.g., GRACE score >140), an early invasive strategy should be prioritized to improve cardiovascular outcomes.

Historical Context

Before TIMACS, the optimal timing for coronary angiography in NSTE-ACS was debated, with some clinicians advocating for a 'cooling-off' period with intensive medical therapy before intervention to reduce procedural risk, while others favored immediate revascularization. TIMACS provided definitive evidence that routine early invasive management for all patients is not superior, but that high-risk cohorts derive clear benefit, effectively refining the 'cooling-off' paradigm.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Based on the pathophysiology of non-ST-elevation acute coronary syndromes (NSTE-ACS), why does the TIMACS trial suggest that an 'early' intervention (within 24 hours) might be less critical for the general population compared to ST-elevation MI (STEMI) cases?

Key Response

In STEMI, there is typically a complete, acute coronary occlusion requiring immediate reperfusion to salvage myocardium. In NSTE-ACS, the vessel is often partially occluded or collateralized. TIMACS suggests that for low-to-intermediate risk NSTE-ACS, there is sufficient stability to allow for medical cooling-down and elective-timing revascularization without increasing the risk of major adverse events, unlike the 'time is muscle' urgency inherent to STEMI.

Resident

A 65-year-old male presents with NSTEMI and a GRACE score of 145. According to the TIMACS subgroup analysis, what is the clinical rationale for prioritizing this patient for the catheterization lab within 24 hours rather than delaying for 48-72 hours?

Key Response

The TIMACS trial demonstrated a significant interaction between risk status and timing of intervention. While the overall trial was neutral, patients with a GRACE score >140 (high risk) showed a 35% relative risk reduction in the primary composite endpoint (death, MI, or stroke) with an early invasive strategy. Therefore, the GRACE score serves as a critical decision-making tool for determining the urgency of the invasive approach.

Fellow

When integrating the results of TIMACS with the later VERDICT trial, how does the definition of 'early' intervention evolve for high-risk NSTE-ACS patients, and what does this imply about the 'biological clock' of myocardial ischemia?

Key Response

TIMACS defined 'early' as <24 hours, while VERDICT looked at a <12-hour window. Both trials converged on the finding that high-risk patients (GRACE >140) benefit from faster intervention. This implies that for the high-risk subset, the NSTE-ACS phenotype behaves more like a 'sub-STEMI,' where the window for preventing progression to significant myocardial infarction is narrower than for the general NSTE-ACS population.

Attending

In a resource-constrained healthcare system where catheterization lab access is limited on weekends, how do you utilize the TIMACS findings to triage NSTE-ACS admissions while maintaining a high standard of medical education for your residents?

Key Response

TIMACS provides the evidence base to safely defer lower-risk patients (GRACE <140) to a delayed strategy (beyond 36 hours) without compromising safety. This allows the attending to teach residents how to prioritize patients based on objective risk-stratification data rather than a 'first-come, first-served' basis, ensuring that high-risk patients are transferred or prioritized while intermediate-risk patients are managed medically in the interim.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The TIMACS trial reported a non-significant primary endpoint but a significant result in a pre-specified subgroup (GRACE score >140). Discuss the statistical risks of over-interpreting this subgroup analysis and how a researcher should design a follow-up trial to validate these findings.

Key Response

Subgroup analyses are prone to Type I errors and are often underpowered. However, because the interaction test in TIMACS was significant (p=0.01), it adds weight to the finding. A follow-up trial (like the later VERDICT) should specifically enroll high-risk patients or use a stratified randomization approach to ensure adequate power for the high-risk cohort, treating 'risk level' as a primary stratification variable rather than a retrospective lens.

Journal Editor

As a reviewer, how would you evaluate the impact of the 33% crossover rate in the 'delayed' arm of the TIMACS trial on the study's ability to demonstrate a benefit for early intervention?

Key Response

High crossover rates (from delayed to early due to clinical instability) often 'dilute' the treatment effect toward the null in an intention-to-treat analysis. A tough reviewer would flag that if the most unstable patients in the delayed arm were moved to the early arm, the delayed arm's outcomes might appear artificially better than they would have been under strict adherence, potentially masking a true benefit of the early strategy.

Guideline Committee

How did the TIMACS trial influence the 'Class of Recommendation' for timing of intervention in the ESC and ACC/AHA NSTE-ACS guidelines, specifically regarding the 24-hour threshold?

Key Response

TIMACS provided the primary evidence for the 24-hour 'early invasive' recommendation. Current guidelines (e.g., ESC 2023) recommend an early invasive strategy within 24 hours for patients with at least one high-risk criterion (Class IA), largely based on the TIMACS subgroup data. It shifted the focus from 'immediate' for all NSTEMIs to 'risk-stratified urgency,' establishing the 24-hour window as the evidence-based benchmark for high-risk patients.

Clinical Landscape

Noteworthy Related Trials

1999

FRISC II Trial

n = 2457 · Lancet

Tested

Early invasive strategy

Population

Patients with unstable coronary artery disease

Comparator

Non-invasive strategy

Endpoint

Death or myocardial infarction at 6 months

Key result: Early revascularization was associated with a significant reduction in the composite endpoint of death or myocardial infarction compared to a conservative management strategy.

2001

TACTICS-TIMI 18 Trial

n = 2220 · NEJM

Tested

Early invasive strategy

Population

Patients with unstable angina or non-ST-elevation myocardial infarction

Comparator

Conservative strategy

Endpoint

Composite of death, myocardial infarction, or rehospitalization at 6 months

Key result: An early invasive strategy significantly reduced the rate of major adverse cardiac events compared to a conservative strategy, particularly in patients with elevated biomarkers.

2009

TIMACS Trial

n = 3031 · NEJM

Tested

Early invasive strategy (within 24 hours)

Population

Patients with acute coronary syndromes without ST-segment elevation

Comparator

Delayed invasive strategy (at least 36 hours)

Endpoint

Composite of death, myocardial infarction, or stroke at 6 months

Key result: The early invasive strategy did not significantly reduce the primary composite outcome compared to the delayed strategy in the overall population, although it showed benefit in high-risk patients.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis